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Abstract— Different research communities have developed 
various approaches to assess the credibility of predictive models. 
Each approach usually works well for a specific type of model, and 
under some epistemic conditions that are normally satisfied within 
that specific research domain. Some regulatory agencies recently 
started to consider evidences of safety and efficacy on new medical 
products obtained using computer modelling and simulation 
(which is referred to as In Silico Trials); this has raised the 
attention in the computational medicine research community on 
the regulatory science aspects of this emerging discipline. But this 
poses a foundational problem: in the domain of biomedical 
research the use of computer modelling is relatively recent, 
without a widely accepted epistemic framing for model credibility. 
Also, because of the inherent complexity of living organisms, 
biomedical modellers tend to use a variety of modelling methods, 
sometimes mixing them in the solution of a single problem. In such 
context merely adopting credibility approaches developed within 
other research communities might not be appropriate.  In this 
paper we propose a theoretical framing for assessing the 
credibility of a predictive models for In Silico Trials, which 
accounts for the epistemic specificity of this research field and is 
general enough to be used for different type of models. 
 
Index Terms— In silico medicine; in silico trials; in silico-
augmented clinical trials; credibility of predictive models; regulatory 
science; biomedical products. 
I. INTRODUCTION 
EFORE  a new medical product can be sold in a country, 
evidence must be provided to the regulatory agency of that 
country supporting the claim that such new product, if used as 
expected and under properly controlled conditions, is safe 
(when it does not worsen the health of the recipient) and 
effective (when the product does improve the recipient’s 
health).  Historically, evidence of safety and efficacy is 
provided through controlled experiments. Those experiments 
involving human volunteers are referred to as clinical trials; by 
contrast those with no humans involved are called pre-clinical 
trials. Some pre-clinical trials involve animals, whereas others 
are based on cell or tissue cultures, tissues and organs from 
cadavers, or machineries (bench tests) designed to reproduce 
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the conditions under which the medical product is expected to 
operate; these are referred to as is in vitro tests. So, until 
recently safety and efficacy were estimated only with controlled 
experiments in vitro, in vivo in animals, or in vivo in humans.  
As described in detail in [1], [2], both the USA and European 
Regulatory Agencies have recently opened in principle to the 
possibility that some of these regulatory evidences are provided 
using computer modelling and simulation, what is normally 
referred to as “in silico trials”.  While for in vitro and in vivo 
methods there is an extensive knowledge and a well-established 
praxis on how to qualify them (i.e. how to assess their 
credibility [3] as predictors of the safety and or the efficacy of 
a new medical product), it is still debated how to assess the 
credibility of in silico methods in a qualification process [4]–
[10]. In most cases, methods to assess credibility are merely 
copied from other research domains, and even applied from 
time to time to different types of models from those originally 
developed for. While the first technical standards specifically 
targeting biomedical applications are appearing [11], there is a 
clear need for a general theoretical framing on the problem, that 
can support these efforts. 
The aim of this position paper is to propose such theoretical 
framing for the problem of assessing the credibility of a 
predictive models for In Silico Trials (ISTs), accounting for the 
epistemic specificity of this research field and is general enough 
to be used for different types of models. 
II. CURRENT PRACTICES FOR CREDIBILITY ASSESSMENT 
A taxonomy of predictive models 
As a first step it is useful to categorise the various models 
used in biomedicine. For the purpose of this position paper, we 
will categorise them as a function of their knowledge content. 
In general, a predictive model can be developed by analysing 
how the quantities to be predicted vary as a function of a set of 
inputs over a large set of experimental observations (data-
driven of phenomenological models), or by leveraging some 
pre-existing knowledge about the physics, chemistry, 
physiology and biology of the phenomenon being modelled 
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(mechanistic models).  While purely phenomenological 
models exist, no model is purely mechanistic.  Also, there are 
some modelling approaches that combine mechanistic 
knowledge and phenomenological evidence (sometime referred 
to as grey-box models).  So, there is a continuum from 
phenomenological to mechanistic modelling, which is well 
represented by the degree of mechanistic knowledge used in 
building each model. 
A second important taxonomy is whether the phenomenon is 
modelled as a continuous or as a series of discrete events. We 
are not referring here to the need to discretise space and time 
for obtaining a numerical approximation, but to models that are 
built assuming the phenomenon being modelled can be 
described by a finite set of discrete states, whereas a continuous 
model describes all quantities as continuous in space-time. 
 
Model Verification & Validation 
Before we go any further, it is important to stress the 
difference between verification and validation, as the two terms 
are often confused, even if are they are tailored to different 
questions.  
Simply speaking, verification tries to answer to the question 
"are we building the system right?", while validation refers to 
the question "Are we building the right system?". The ASME 
V&V 40 defines verification as "the process of determining that 
a computational model accurately represents the underlying 
mathematical model and its solution from the perspective of the 
intended uses of modeling and simulation". In other words, we 
need to test that all the implemented code and the solver 
approximations of the computational model lead to numerical 
results that are "sufficiently near" (i.e., taking into account 
numerical approximations and discretization errors) to the exact 
analytical solutions of the mathematical formulation of the 
model at hand.  
The goal of Validation is instead to assess how well the 
computational model represents the reality it is supposed to 
represent. That is, with validation we check that the model well 
reproduces the biological, physical, mechanical features of the 
real phenomenon. To this end, results coming from simulations 
are compared against results and measurements coming from in 
vivo/in vitro benchmark experiments, usually executed under 
controlled conditions. 
 
VV&UQ of engineering models 
In engineering sciences, there are well established practices 
for assessing model credibility for different industrial sectors, 
such as aviation, civil, nuclear, etc. These are usually referred 
to as Verification, Validation, and Uncertainty Quantification 
(VV&UQ, or sometimes referred to more simply as V&V). A 
fundamental element in model credibility is what we will call 
here Applicability, which is how far from the conditions under 
which the model has been validated, the predictions remain 
credible.  In the following we provide a brief description; more 
details can be found in [12], [13]. 
Any predictive model can be formalised as:  
𝑂" = 𝑓(𝐼), 
where 𝑂"  is an estimate of O, the quantity we want to predict; 𝑓() represents the predictive model; and I the set of input values 
(or parameters) of the model. In general, I and 𝑂" are scalar, 
vector, or tensor quantities.  
  
1) Context of use 
The first step in the credibility assessment for a model is the 
definition of the Context of Use (CoU). This is a detailed 
explanation of how we plan to use the model in the regulatory 
process. In particular, we need to define precisely which 
decisions we would want to make using the model, how the 
predicted quantity O informs such decisions, what is the 
structure of f(), which inputs I it requires and how they are 
determined, what is the uncertainty 𝜎(𝐼) affecting such inputs, 
and what is the range of values that I can possibly assume when 
the model is used in that CoU.  
 
2) Verification 
The second step is verification, which is usually split into 
code verification and model verification. Code verification is 
essentially a quality assurance practice for the software we use 
to solve the model, and a stability check for the numerical 
algorithms it implements. Software quality assurance is done 
with methods typical of software engineering, such as 
regression tests, or unit tests. Numerical solvers 
implementations are tested to check their stability, their rates of 
convergence, their computational efficiency, etc. Commercial 
codes tend to have their own extensive code verification. 
Model verification, also called calculation verification or 
solution verification, mainly aims at evaluating the 
approximation errors, i.e. the quantification of the error caused 
by the approximated solution of the mathematical model, 𝜈*(+). 
Once the code verification is completed, one can assume that 
any approximation error is only due to the numerical solution, 
and not to any coding errors. Methods for the verification of the 
model depend on the model’s structure, and the choice of 
numerical methods used to solve it. For example, for continuum 
models these may include simple time-step or grid convergence 
analysis (e.g., mesh convergence analysis for finite element 
models).   
Normally, for mechanistic approaches, if a particular set of 
inputs, I*, exists which simplifies f() to the point where an 
analytical solution is possible, this particular solution f(I*) is 
called a benchmark problem, and 𝜈*(+) can be easily quantified 
against it. When it is difficult or impossible to formulate a 
benchmark problem, alternative methods are available such as 
the method of the exact solution and method of the 
manufactured solutions [14].  
Another important element in the model verification process 
is the parameter exploration. The model is executed multiple 
times, each run with a different set of inputs, in order to sample 
the input space for the range of admissible values, consistent 
with the problem being modelled. The goals are to: (i) ensure 
that the model runs correctly for all admissible inputs, and (ii) 
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that the output vary smoothly with the input. If any of these 
conditions are not met, it may indicate a problem with the 
model, for example numerical instabilities. 
It should be stressed, that the separation between code 
verification and model verification can be sometimes a bit 
artificial.  For example, advanced modelling software platforms 
such as ANSYS [15] provide the modellers with a full-blown 
programming language to describe the model.  However, in 
complex cases, such languages can be used to describe specific 
algorithmic behaviours.  In such case, the code verification 
ANSYS provide would not be sufficient, because the additional 
code written by the user would need itself a code verification. 
For completeness, some technical standards, such as V&V 40 
[11], consider also as part of the verification, the evaluation of 
the use error, which is due to human errors of the practitioner 
(for example transcription errors). 
 
3) Validation 
Once the verification is complete, a validation study must be 
conducted. If it is possible to carry out an experiment so well 
controlled that the measured uncertainty of the outcome 
variable, 𝜎(𝑂), is negligible, then the prediction error ,-𝑂 − 𝑂"-/ can be entirely be ascribed to the model. When this 
condition is not met, the definition of predictive accuracy 
becomes more complex, and should be framed within the 
context of uncertainty quantification and sensitivity analysis. 
 
4) Uncertainty quantification & Sensitivity Analysis  
Uncertainty quantification (UQ) & Sensitivity Analysis (SA) 
are essential parts of the validation process. Uncertainty 
quantification refers to the estimation on how the stochastic 
error that affects the input propagates through the model into 
the output: 𝜎,𝑂"/ = 𝑓(𝜎(𝐼)) 
 
where 𝜎() represents the variability of a quantity over repeated 
measurements/predictions.  Sensitivity analysis is a post-hoc 
analysis done on the results of the uncertainty quantification, to 
evaluate which elements of the input set, I, are the main drivers 
of output variability.  For a systematic review of the methods 
used in general engineering, see [16]. 
 
5) Applicability 
The term “Applicability” refers to whether the validation 
evidences provided are relevant within the CoU of the model.  
For example, if a metal structure may be occasionally subjected 
to loads large enough to induce plasticity in the metal, a 
validation conducted only with low loads where the metal 
behaves in purely elastic fashion would not provide enough 
evidence that the model is credible when higher loads are 
involved, and plasticity may occur. For phenomenological 
models, such as machine learning, applicability is framed in 
term of the generalisation error [17].  For mechanistic models it 
is related to the concept of “limit of Validity” of the theory used 
to develop the model [18]. 
 
6) Technical standards 
Probably the most important effort in this field is the one of 
the American Society of Mechanical Engineering (ASME) 
standardisation committee “V&V: verification and validation in 
computational modeling and simulation” [19].  It is articulated 
in a number of sub-committees, each focusing on a specific 
industrial sector; the one of interest here is the “V&V 40 
Verification and Validation in Computational Modeling of 
Medical Devices” [11]. 
 
III. THE THEORETICAL FRAMING OF CREDIBILITY ASSESSMENT 
From practice to theory 
In the following section, we propose a formal framing for 
carrying out credibility analyses for in silico models in 
biomedical sciences and highlight the assumptions on which 
such practices are built upon. Thus, providing a theoretical 
framework which can be used to evaluate if and when such 
practices are valid. 
Assume we can measure Oi, the quantity we want to predict, 
under certain conditions, 𝑖 = 1,… , 𝑛. The predictive error of 
model 𝑓(), Af, can be quantified as the root mean square 
difference between the model prediction and the experimental 
measurement, 
 𝐴* = 6∑ (𝑓(𝐼8) − 𝑂8)9:8;< 𝑛 , 𝐼8 ∈ ℑ, 
 
with ℑ the set of all admissible inputs defined by all possible 
conditions that may occur in reality for the phenomenon being 
modelled.  
Because these experiments are usually complex, expensive, 
and time-consuming, it is almost always true that the number n 
of conditions we can test represents only a small sample of ℑ.  
Thus, simply reporting the value of Af for a small number, n, of 
experiments is not enough to establish the model credibility. 
We need also to make some assumptions on the distribution and 
smoothness of 𝐴*(𝐼) over the entire domain ℑ.  But to do this, 
we need to separate the various sources of error. The predictive 
error can be decomposed as: 
 𝑂 − 𝑂" = 𝛼@ = 𝛼+ + 𝜀* + 𝜈*,+, 
 
where 𝛼@ is the overall predictive error, which can be 
decomposed into an aleatory error, 𝜶𝑰, arising from the 
intrinsic randomness or variability of the data used to inform 
the model, and an epistemic error, 𝜺𝒇, that influences both the 
prior knowledge and the phenomenological derivation. Last, 
when 𝑓() is too complex to be solved analytically, the model 
prediction is affected also by a numerical approximation 
error, 𝝂𝒇,𝑰, which depends on the structure of the model as 
instantiated for the inputs 𝑓(𝐼). In general, we can only quantify 
IEEE	JOURNAL	OF	BIOMEDICAL	AND	HEALTH	INFORMATICS,	VOL.	XX,	NO.	X,	XXX	201X	1	 
 
 
4 
𝛼@ through controlled experiments; to separate the three 
components of this error, we need to make some assumptions, 
which when valid enable the VV&UQ process. 
The first assumption is that 𝛼* has mean nought.  If this is 
true, then we can write: 
 𝑎𝑣𝑒,-𝑂 − 𝑂"-/ ≈ 𝜀* + 𝜈*,+. 
 
The second assumption is that the numerical approximation 
error is negligible, compared to the epistemic error (𝜈*,+ =𝑜(𝜀*)).  If this is true, then: 
 𝑎𝑣𝑒,-𝑂 − 𝑂"-/ ≈ 𝜀*. 
 
The third and last assumption is that all the uncertainty 
affecting 𝛼@ is due to the aleatoric component of the prediction 
error.  If this is true, then: 
 𝜎(-𝑂 − 𝑂"-) ≈ 𝛼+, 
 
where 𝜎 is the variability of the prediction error. Only if these 
assumptions are justified, we can evaluate the credibility of a 
predictive model through the standard VV&UQ process:  
 
- First, we need to define the CoU of the predictive model, 
and the maximum acceptable predictive error.  
 
- Then we need to check that the inputs we provide to our 
predictive models are accurately measured, in the sense 
that the measurements we use to quantify them are affected 
by small systematic errors, if any; this would confirm the 
first assumption.  
- Obtain some values for the output O, under conditions for 
which the epistemic error is known to be nought. The 
predictive error for such conditions provides an estimate of 
the numerical approximation error; if this is much smaller 
than the maximum acceptable predictive error, it would 
confirm the second assumption.  
- With the first two assumptions checked, we can run 
multiple validation experiments and obtain an estimate of 
the epistemic error.  By looking at how the epistemic error 
varies for different values of the inputs, we can also inform 
the applicability of the model, for example defining the 
limits of validity of the model in terms of input values. 
- Last, we need to confirm the third assumption, that all 
uncertainty comes from the aleatoric component. This is 
not easy, and it requires some reflections on the internal 
structure of the model. If the third assumption is confirmed, 
then we can run an uncertainty quantification study, 
observing how the variability of the inputs propagates into 
the model predictions.  
 
A final consideration on the concept of Applicability is 
needed. The goal is to estimate the predictive error of the model 
as a function of the input, over the admissible range in the input 
space, defined by the CoU. Models are usually validated over a 
limited set of possible input values, which might provide a 
sparse sampling of such error function. To deem such sparse 
sampling sufficient for establishing the credibility of the model, 
we make two additional assumptions.  
The first assumption regards the dependence of the model 
prediction error on the input; the variation of the prediction 
error should be smooth, i.e. for similar input values the model 
should produce similar prediction errors, and the difference in 
the error should be negligible compared to the prediction error 
of the model for any input; formally, if 𝐼< ≈ 𝐼9 in some sense, 
then: 𝛼N(𝐼<) − 𝛼N(𝐼9) ∝ 𝑜[𝛼N(𝐼8)]. 
 
The second assumption is that the credibility of the model is 
a decreasing function of the distance between the input values 
for which the validation was conducted, and the input values for 
which the model is being used in that specific CoU. As we will 
discuss in the following section, these assumptions are related 
to the type of model being used. 
IV. CREDIBILITY ASSESSMENT OF BIOMEDICAL MODELS 
Why biomedical models are different 
The process to assess the credibility of a predictive model 
described in the previous sections was developed for general 
engineering applications, where there is usually fairly robust 
mechanistic knowledge of the process being modelled; thus, 
most of these models are physics-based, with a major 
mechanistic component that describes continuum field 
problems using systems of ordinary differential equations 
(ODEs) or partial differential equations (PDEs), solved with 
well-established numerical methods.   
The situation in biomedicine is rather different. For many 
biological processes the mechanistic knowledge available is 
partial or totally absent.  In many cases the observations used to 
develop this mechanistic knowledge are affected by 
considerable errors, and sometimes these are not even 
quantitative. The complexity of most biological processes is 
hardly reducible; for example in most cases the assumption of 
scale separation involves considerable errors [20].  This has 
forced the researchers in this field to use a wide range of 
modelling methods, including continuum field models, agent-
based models, machine learning models, and even 
combinations of these, like orchestrated multiscale models. 
The standard VV&UQ described before is usually valid for 
continuum field models, lumped-parameter and compartment 
models, diffusion-reaction models, etc. But for a few types of 
models used in biomedicine further discussion is needed. 
 
Phenomenological models 
The distinction between statistical and machine learning models 
is debatable [21], so here we prefer to generically refer to 
phenomenological models.  Is VV&UQ useful to establish the 
credibility of phenomenological models? Code verification 
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applies to any software artefact, and this includes also 
phenomenological models. Strictly speaking the concept of 
model verification does not apply, since there is not 
mathematical model to solve numerically; some authors use the 
term model verification to mean validation (e.g. [22]).   
Also, the concept of validation is quite different: to develop a 
phenomenological model we need a number of inputs sets for 
which the true (i.e. experimentally observed) output set is 
known, which is another definition of validation set. The 
difference between the predictions of the final model and the 
true values of the training set is called training error. 
Unfortunately, because the model is developed by induction, 
the training error is in no way predictive of the so-called test 
error, which is the error the machine learning model will show 
when tested against a new validation set. In a sense, the 
evaluation of the test error is the closest thing to validation for 
machine learning models. 
But the biggest issue with machine learning models is 
Applicability. First, phenomenological models are highly 
environment-specific, and any changes of the original field 
environment may result in a significant different outcome. 
Thus, they can show a considerable degree of stiffness in the 
prediction error, when not optimally trained against adversarial 
perturbations [23]. This means that in some cases the predictive 
errors may not have the smoothness the concept of applicability 
requires. But there are deeper issues. Mechanistic models are 
usually built under some hypotheses (idealisations) which are 
acceptable only within a range of input conditions, called limit 
of validity of the theory. For these models we can expect the 
predictive error to be fairly constant (and small) while the 
inputs are within the limits of validity, and then start to increase 
the further we go in the inputs space beyond these limits.  None 
of these assumptions can be made for a phenomenological 
model.  Even if we found small prediction errors for all inputs 
of both the training and test set, in principle nothing will 
guarantee that for an input not included in these two sets the 
prediction error is much larger.   
One specific issue is called Concept Drift [24]. This indicates 
that the statistical properties of the output, which the model is 
trying to predict, change over time in unforeseen ways. Of 
course, in principle the risk of Concept Drift also affects 
mechanistic models; if the model has been designed and 
validated over a normal population, and then a characteristic of 
the population changes, e.g. obesity becomes increasingly 
common, one might observe a progressive loss of predictive 
accuracy in all types of models.  But in a mechanistic model the 
inputs are carefully selected to include all factors that might 
significantly affect the output, so in this case a good model 
would include body weight among the input variables. In 
machine learning the input set is selected from the available 
information to maximise the predictive accuracy on the training 
set, the risk of not including body weight in the training set if 
not all patients have normal weight, can be much higher.  
Recently, the FDA published a report entitled “Proposed 
Regulatory Framework for Modifications to Artificial 
Intelligence/Machine Learning (AI/ML)-Based Software as a 
Medical Device (SaMD) - Discussion Paper and Request for 
Feedback” [25]. Even if the target is different (SaMD are 
software artefacts directly involved in the care process of 
individual patients), some conclusions are relevant here. In 
short, FDA advocates for these products the use of total product 
lifecycle (TPLC) regulatory approach. At risk of 
oversimplifying, this means that a phenomenological model is 
never truly validated, and its predictive accuracy should 
periodically re-tested. In the best-case scenario, every time the 
model is used to make a prediction, we should later on collect 
the true value for that case and recalculate the average 
predictive accuracy; if this degrades below an acceptability 
threshold the use of the model should be suspended. 
 
Agent-based models 
Agent-Based Models (ABM), are mechanistic models, where at 
least some of the inputs are discrete. Most ABM represent 
agents as finite-state machines, capable of assuming a limited 
number of discrete states, moving and interacting in a space-
time continuum over which a number of fields are also 
computed.  
In some implementations, only the state transitions are handled 
as discrete rule-based events, whereas the motion of the agents, 
and changes in the continuum fields, are expressed by coupled 
continuum models formulated as systems of ordinary or partial 
differential equations [26]. In some others, space, time, and 
field quantities are discretised, so that the entire system can be 
modelled with discrete-rule based events [27].  But this is a 
choice made for modelling convenience, as only state variables, 
and the birth-death of the autonomous agents are epistemically 
discrete; all the other variables remain conceptually continuous. 
Generally speaking, the VV&UQ approach is appropriate to 
establish the credibility of an ABM. The epistemically 
continuous parts of the model require extensive model 
verification, whereas the inherently discrete ones require only 
code verification, as they involve only algebraic calculations; 
however, because of the possibility of local instabilities, a 
parameter exploration is recommended. Validation and 
uncertainty quantifications can be performed normally.  
Applicability requires instead some additional cautions. The 
discrete nature of the ABMs does not ensure the smoothness of 
the predictive error over the input space, although parameter 
exploration can reassure of the smoothness of the predictions 
over the inputs space.  The state-transition rules are often based 
on theories informed by biological observations, which have in 
some cases faced only limited falsification attempts, and in 
general are incomplete descriptions of the causal relationships. 
For all these reasons ABMs predictions made far from the 
validation sets in the input space should be used with limited 
confidence. 
 
Multiscale and multi-physics models 
Because the assumption of scale separation usually involves 
significant errors for living organisms, it is becoming quite 
popular for biomedical problems to use multiscale models.  
Also, sometimes it is convenient to break down the problem 
into multiple models, each capturing an aspect of the 
phenomenon being modelled (sometime these are referred to as 
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Multiphysics models). In both cases, we are not dealing with a 
single model, but with an orchestration of multiple component 
models. In the case of multiscale model these component 
models are coupled over space-time through homogenisation / 
particularisation operators that transform quantities across 
space-time scales.  In the case of Multiphysics models there is 
also sometime the need to interpose in the orchestration 
between two models a transformation model that remaps 
certain properties across the specific physics theories. 
As discussed in [18], model orchestrations pose peculiar 
problems when used to falsify theories.  The same reasons make 
it very difficult to discuss if the traditional VV&UQ approach 
to model credibility is appropriate for this class of models. An 
in-depth discussion is beyond the scope of this position paper: 
interested readers can explore the variety of approaches 
reported in the literature [28]–[34]. But the general philosophy 
that is emerging is that the credibility of multiscale models 
should be assessed first by carrying out an individual VV&UQ 
for each single-scale component model, and another for their 
multiscale orchestration, with validation experiments relevant 
to the CoU. In certain complex models, homogenisation and 
particularisation functions are models themselves, and thus they 
also should have individual VV&UQ assessments. 
Also, uncertainty quantification is challenging with models’ 
orchestrations: due to be combinatory nature of the problem 
brute force approaches such as Monte Carlo method is most of 
time prohibitive.  In these cases special approaches are required 
such as Bayesian multi-fidelity schemes [35], or Gaussian 
processes [36] .  
 
Applicability for non-mechanistic models 
In the most general case, the model 𝑓() is built composing 
phenomenological and mechanistic knowledge. Mechanistic 
knowledge derives from scientific theories that have so far 
resisted falsification attempts so extensively that the scientific 
community accept them as operationally true; these are 
sometimes referred to as first principles. A good example of 
such theory is Newton’s second law of dynamics. 
Phenomenological models are entirely and exclusively based on 
observational data; these can range from simple statistical 
regressions, to sophisticated machine learning models. The 
model 𝑓() can then be written as: 
 𝑓(𝐼) = 	𝑓,𝜇(𝐼), 𝜓(𝐼, 𝐽)/. 
 
Where 𝜇(𝐼) is the mechanistic part of the model, 𝜓(𝐼, 𝐽)	is the 
phenomenological model and J is a set of observed data 
(sometimes referred to as training set). The error of the model 
can then be written as: 
 𝜀,𝑓(𝐼)/ = 	𝜀 V𝜀W(𝐼), 𝜀X(𝐼, 𝐽)Y. 
 
The question of applicability is related to the shape of 𝜀(𝑓(𝐼)): 
if the error is nearly constant over a wide range of I, we can 
predict far from the input values used in validation with small 
risk; if the error varies considerably over I, then extrapolation 
is risky. In most cases, there is a reliable understanding of how 
the observational error 𝜀(𝐼) (i.e. instrumentation accuracy) 
varies across the range of observed values. Since the structure 
of mechanistic models is explicit (white box models), it is in 
general possible to estimate the shape of its error from that of 
the inputs: 𝜀W(𝐼) ≈ 𝜇(𝜀(𝐼)). It is instead very difficult to 
estimate the shape of the error affecting the phenomenological 
part of the model, 𝜀X(𝐼, 𝐽), due to its dependence on both the 
inputs and the training set, and the uncertainty on the structure 
of 𝜓(𝐼, 𝐽) (black box model).  
This has an important practical implication: for predominantly 
mechanistic models error propagation studies make it possible 
to estimate the shape of the prediction error over the input 
space, and guide on deciding how far from the validation region 
the model can still accurately predict; for phenomenological 
models this is not possible, and thus model applicability should 
be limited to the range of validated input values.  
 
V. POSSIBLE CONTEXT OF USE FOR IN SILICO TRIALS 
The credibility of a predictive model can be evaluated with 
respect to CoU aimed at reducing, refining, or replacing an 
experimental study conducted in vitro, or in vivo either on 
animals or humans (clinical trial). While each of these scenarios 
is potentially relevant for different reasons, we will focus here 
on the use of predictive models to reduce the number of patients 
involved in and/or the duration of a clinical trial. 
 
The standard clinical trial 
The effect of an intervention i is tested clinically by forming 
a cohort, 𝛬:, of n physical patients (each represented by a 
patient j descriptor set Ij), who are selected to be representative 
of the target patient population by a set of inclusion and 
exclusion criteria. Each patient in the cohort is then randomly 
allocated to an intervention i, and the effect measured through 
the endpoint, e. An intervention is considered effective if the 
desired effect on e is observed. For example, in the case of a 
treatment/no treatment design, the average value of e in the 
treated subset of the cohort is significantly better. Such 
conclusion is considered credible only if the statistical test used 
in the evaluation of the difference in endpoints has large power, 
i.e. if the statistical power 𝛺(·) is large enough (e.g. > 80%). As 𝛺 typically increases with n, larger cohorts can provide stronger 
statistical evidence.  
 
In silico-augmented clinical trial 
Assume 𝑓(𝐼], 𝑝, 𝑡) is a mathematical model that can predict 
changes in the endpoint e for each patient, p, and for either the 
naïve (i.e. no treatment, t=0), or the intervention (t=1). The 
clinical accuracy of such model for patient I can be expressed 
as: 𝜀(𝐼]) = |𝑒 − ?̂?| = -𝑒 − 𝑓(𝐼], 𝑖)-, 
 
 Where ?̂? is the prediction of the endpoint 𝑒. Now, the 
fundamental idea behind in silico-augmented clinical trials is 
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as follows: 
Proposition 1 (in silico-augmented clinical trials): If each 
patient in a cohort is represented by Ij, the effect of the 
intervention is represented by e, and there is a mathematical 
model 𝑓(𝐼], 𝑖) that can predict e with sufficient accuracy ε given 
I and the treatment i, we can then generate virtual patients by 
simply creating new Ij’ sets that are possible in the target 
population, and use the model 𝑓() to do an in silico clinical trial 
on these virtual patients, in order to predict their values of e. 
The cohort 𝛯@ of m virtual patients could be used to 
supplement cohort 𝛬: in order to decrease its size for the same 
statistical power. 
The key issue is whether the test of a relevant statistical 
hypothesis on the effect of i, using the virtual cohort, 𝐻,𝛩"; 𝑖, 𝛯@/, where 𝛩 parameterises the distribution of 
endopoints e, can be considered a reliable replacement of 𝐻(𝛩; 𝑖, 𝛬:).  
To answer affirmatively to this question, we should to 
demonstrate: 
1) ∀𝐼] ∈ 𝛯@, ∃	0 < 𝑛 < ∞, such that 𝐼] ∈ 𝛬:; i.e. that 
every virtual patient represented by the descriptor set 
Ij is a plausible virtual patient, in that we would 
observe that descriptor set in physical patient, if the 
physical cohort was sufficiently large. 
2) the clinical accuracy of the predictor 𝑓() estimated on 
the cohort 𝛬: is representative of the accuracy of the 
predictor on any other (larger) cohort, and such 
accuracy is clinically meaningful, i.e. ∀𝐽, 𝑒,𝐼]/ < 𝜀.  
3) Last, that ∀		0 < 𝛽 < 1, ∃𝑚(𝛽), 𝑛(𝛽) < ∞,     such 
that 𝛺 V𝐻,𝛩"; 𝑖, 𝛯]/Y > 𝛽	∀𝑗 > 𝑚(𝛽), and 𝛺,𝐻(𝛩; 𝑖, 𝛬o)/ > 𝛽	∀𝑘 > 𝑛(𝛽); i.e. for sufficiently 
large virtual and physical cohorts, the conclusions of 
the effect of the intervention assessed from virtual and 
physical cohorts are identical. 
Furthermore, while it is not strictly necessary, in some cases: 
4) We may also need to prove that for some relevant 
measure of discrepancy, 𝑑r, there are 	𝑚, 𝑛 < ∞, such 
that the distance 𝑑r(𝛯@, 𝛬:) < 𝛿, for small 𝛿 > 0; i.e. 
the sets of patient descriptors in the virtual and 
physical cohorts are sufficiently similar when the 
cohorts are sufficiently large.  
 
Virtual Patients plausibility 
To demonstrate that 𝛯@ ⊂ 𝛬: we need to find other cohorts 
where I (or more likely one element of I) have been observed 
on a much larger cohort. There are two practical difficulties.  
In many cases large enough cohorts are available only for 
healthy subjects; in that case we need to demonstrate that the 
range of admissible values observed in the normal population 
does not change in the diseased population: for example, we can 
take the male-female ratio from general population studies, 
because no disease changes the gender. 
The second problem is that rarely all elements of I have been 
observed in a large cohort, so we are forced to take the 
admissible ranges for different elements, from different 
populations. This is fine, as far as we can demonstrate that the 
elements of I are independent, i.e. the variation of one element 
does not affect the variation of the others. Alternatively, we 
need to estimate the joint distribution for this set, which might 
not be easy. 
 
Meaningful clinical accuracy 
Showing 	𝑒(𝐼) ≤ 𝜀	 is in general not easy. The first problem 
is how the clinical accuracy is estimated. In the simplest cases, 
both I and e are observed at the same time, but in some cases 𝑓() is a risk predictor, in the sense it predicts an endpoint that 
can be observed much later using I observed now. A typical 
example is the predictor of hip fracture risk, where models 
predict strength from CT images and currently available clinical 
data, and this strength is used as a predictor of the risk of 
fracture, which may occur even five or ten years later. In these 
cases, three possible approaches can be used: 
 
a) The gold standard is a prospective evaluation with a 
dedicated clinical trial; a cohort of patients is enrolled, 
all quantities in the cohort descriptor I measured today 
are used to predict who will fracture and who will not 
in the next X years; recall all patients after X years and 
check who did actually fracture and who did not. This 
can be a very expensive trial. If X is long many will be 
lost to the follow-up and, if the incidence of fracture is 
low, a large number of patients should be enrolled to 
observe enough fractures.  
 
b) A second approach uses long-term observational 
databases, where both I and e are observed regularly 
over X years. Any time after that, one may take the I 
observed at the beginning of the study and use them to 
predict how many will have endpoint e after X years. 
The main limitation is that the data were not collected 
specifically to validate a specific model. Thus, most 
likely the information available is not exactly what 𝑓() 
needs to be properly informed, so it is not certain how 
much of the observed inaccuracy is due to the model, 
and how much of this is due to poor quality of the data. 
 
c) If a cohort can be formed with a portion of the patients 
having the endpoint over threshold now (i.e. they have 
a fracture), and the rest not, and we measure the 
necessary I now, we will be able to check how good 𝑓() is in separating the positive and the negative cases; 
this is sometimes called stratification accuracy. A 
good stratification accuracy is a necessary but not 
sufficient condition for a good predictive accuracy; if 
a predictor has a poor stratification accuracy for sure 
it will also have a poor clinical accuracy in prospective 
evaluations; but a good stratification accuracy does not 
automatically ensure an equally good prospective 
accuracy. 
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Representativeness of the accuracy: power and applicability 
If the physical cohort used to evaluate the clinical accuracy 
is large enough, this problem can be formulated as a statistical 
power problem. But even when there are enough data to achieve 
sufficient statistical power, a more general problem of 
applicability remains. In order to be useful, a model should be 
able to make predictions for input values that are different from 
those used to assess its accuracy; but we do not know the 
predictive accuracy of the model for those new inputs. 
Considerations on the general regularity of physical quantities, 
and about the assumption that model accuracy should degrade 
smoothly in the sense that predictions made for similar inputs 
should present similar predictive accuracy, allow to assume that 
a degree of extrapolation is possible, in the sense that the model 
can be considered reliable even when used to predict for inputs 
different from those observed in the clinical validation cohort 
(Applicability).  
 
Similarity measures in cohort expansion 
The concept of Applicability does have another important 
implication for the use of predictive models for cohort 
expansion. A possible approach is described in [37], [38]. The 
idea is: 
 
1. Let 𝐿(𝑒 ∈ 𝛬) be the likelihood of an intervention 𝑖 given 
the responses 𝑒 observed over the physical cohort 𝛬. 
Assuming conditional independence,  𝐿(𝑒 ∈ 𝛬) ∝∏ 𝑃(𝑒|𝑖])o];< ; in other words, the likelihood is proportional 
to the product of the probability distribution of effect e, for 
each intervention level. In the simplest case of a single 
intervention level, 𝐿(𝑒 ∈ 𝛬) 	∝ 𝑃(𝑒yz{|y) 	× 	𝑃(𝑒:~	yz{|y). 
 
2. According to Bayes theorem, the posterior probability that 
the intervention 𝑖 produces the desired effect 𝑒 is 𝑃(𝑒|𝑖) =(8|{)×	(8)({) , where 𝜋(𝑖) is the prior probability, and 𝑃(𝑒) is 
the marginal probability of 𝑒. 𝐿(𝑖|𝑒) and 𝑃(𝑒) are observed 
experimentally, and thus their precision is limited by the 
numerosity of 𝛬. But if we can elicit 𝜋(𝑖) from the virtual 
patient cohort 𝛯, whose size 𝑚 can be freely increased, we 
can boost the power of 𝑃(𝑒).  
 
3. In most cases, the confidence we have on 𝐿(𝑖|𝑒) is greater 
than that we have on 𝜋(𝑖), which is elicited, but its power 
is insufficient because the cohort of physical patients 𝛬 is 
too small. Adding a prior may improve the posterior 
precision, but the risk with this approach is that if 𝑚	 >>	𝑛, the posterior probability 𝑃(𝑒|𝑖) might be influenced 
excessively by the virtual patients. So, we look for the 
smallest number of virtual patients sufficient to attain the 
desired power. 
 
Regarding the selection of the number of virtual patients, 
Haddad et al. [38] suggest to begin by fixing the maximum 
number (strength) of virtual patients, 𝑛@|, and adjust the 
actual number used, 𝑛 = 𝑛@|𝐹, by multiplying it for a 
discount factor, 
 𝐹 = (𝑝|𝜅, 𝜆) = 1 − 𝑒𝑥𝑝 −V𝑝𝜆Y, 
 
which depends on a measure of compatibility of the virtual 
and real patients (they call it a Bayesian p-value) and two 
parameters, (𝜅, 𝜆), controlling the penalisation. These 
parameters are fixed on an ad hoc basis. 
This so-called p-value is arguably a measure of (stochastic) 
dissimilarity (i.e. compares the posterior distributions) between 
the parameter of interest, 𝜃, from the trial using a minimally 
informative prior on the augmented cohort (𝜃) and the one 
obtained using the virtual cohort only (𝜃), 
 𝑝 = 𝑃[𝜃 ≤ 𝜃], 
 
estimated using the simulated data. 
They argue that as 𝑝 → 1, the compatibility of the virtual 
cohort is greater and thus 𝑛 → 𝑛@|. This seems to indicate 
they regard larger values of 𝜃 as indicating compatibility with 
the real patients. Hence, if the posterior distribution using the 
real data and a flat prior has more mass towards smaller values 
of 𝜃, compared to the posterior distribution using the virtual 
cohort, the method indicates compatibility with the real data 
and allows for a larger contribution from the simulated patients. 
 
VI. CONCLUSIONS 
The aim of this position paper is to propose a theoretical 
framing for assessing the credibility of a predictive models for 
In Silico Trials, which accounts for the epistemic specificity of 
this research field and is general enough to be used for different 
types of models. We also proposed mathematical formalisms 
for one particular application of in silico methods, where 
validated predictive models are used to augment clinical trials 
on physical cohorts by simulating the clinical trial of a new 
intervention on virtual cohorts. A recap is proposed in Table 1. 
The potential scope for in silico methods is of course much 
broader: in principle in silico methods can be used also for 
reducing, refining, or replacing experimentations done in vitro, 
or in vivo. 
The approach that most practitioners have adopted so far is 
conservative and aims to frame in silico methods within the 
current structure and logic of testing new medical interventions. 
In most cases we seek to demonstrate equivalence with the 
experimental method we aim to replace, but the general logic 
behind remains the same. The development of in silico methods 
has much deeper implications.   
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In Silico Augmented Clinical trials: credibility 
 
Goal: Create a cohort 𝛯@ of m virtual patients to supplement the cohort 𝛬: of n real patients in order to decrease its size for the 
same statistical power 
 
Requirement Mathematical Formulation Proposed methodologies to assess requirement 
1) Assess the credibility of 
virtual patients 
∀𝐼] ∈ 𝛯@, ∃	0 < 𝑛 < ∞: 𝐼] ∈ 𝛬:; Find other cohorts where I (or more likely one element of I) have 
been observed on a much larger cohort. 
Weaknesses:  
1) large enough cohorts are available only for healthy 
subjects; demonstrate that the range of admissible values 
of the normal population does not change in the diseased 
population 
2) Rarely all elements of I are observed in a large cohort; take 
the admissible ranges for different elements from 
different populations, if the elements of I are independent. 
Alternatively, try to estimate the joint distribution for the 
set. 
2)Assess that the clinical 
accuracy is meaningful 
∀𝐽, 𝑒,𝐼]/ < 𝜀. Possible approaches: 
1) Use prospective evaluation with a dedicated clinical trial; 
Weakness: Evaluation can be done only at the end of the 
trial. 
2) Use of long-term observational databases. Weakness: 
Uncertainty about observed inaccuracy (i.e., is due to the 
model or to inadequacy of data coming from other 
experiments?). 
3) Use stratification accuracy. Weakness: Necessary but not 
sufficient condition for a good predictive accuracy. 
3)Assess that, for successfully 
large cohorts, the 
conclusions of the effect of 
the intervention assessed 
from virtual and physical 
cohorts are identical 
∀		0 < 𝛽 < 1,∃𝑚(𝛽), 𝑛(𝛽) < ∞:    𝛺V𝐻,𝛩"; 𝑖, 𝛯]/Y > 𝛽	∀𝑗 > 𝑚(𝛽), 
and 𝛺,𝐻(𝛩; 𝑖, 𝛬o)/ > 𝛽	∀𝑘 > 𝑛(𝛽); 
Formulate the problem as a statistical power problem, when 
the cohorts are large enough. Weakness: Not sufficient to make 
predictions for input values outside those used to assess 
accuracy; Assumptions about regularity of physical quantities 
and smoothness of model accuracy degradation may allow 
application on inputs outside the one used in the clinical 
validation cohort to some extent (Applicability). 
4) (Optional) Assess that  
sets of patient descriptors in 
the virtual and physical 
cohorts are sufficiently 
similar when the cohorts are 
sufficiently large. 
∃	𝑚, 𝑛 < ∞:	 𝑑r(𝛯@, 𝛬:) < 𝛿, 
for small 𝛿 > 0 (for some 𝑑r)  Proceed as for point 3. 
Cohort Expansion 
Methodology: Elicit the prior probability 𝜋(𝑖)	that an intervention i produces a desired effect 𝑒 from the virtual patient cohort 𝛯@, 
whose size 𝑚 can be freely increased, to boost the power of 𝑃(𝑒), marginal probability of 𝑒 and to better estimate the posterior 
probability 𝑃(𝑒|𝑖).  Weakness: if 𝑚	 >> 	𝑛, the posterior probability 𝑃(𝑒|𝑖) might be influenced excessively by the virtual patients. 
In this case it is possible use the approach by Haddad et al. to estimate the size of the virtual cohort. 𝐼] patient j in a given cohort; 𝛯@ cohort of virtual patients; 𝛬: cohort of real patients; 𝑒 effect of a given intervention (endpoint) ?̂? is the prediction of the endpoint 𝑒 
i intervention (i.e., drug or medical device) 𝑑r a given measure of discrepancy 
ε accuracy of the mathematical model 𝑓(𝐼], 𝑖) in reproducing e   𝐻,𝛩"; 𝑖, 𝛯@/ statistical hypothesis on the effect i, using the virtual 
cohort 𝐻(𝛩; 𝑖, 𝛬:) statistical hypothesis on the effect i, using the real cohort, 𝛩"	the set of endpoints of ?̂? 𝛩 the set of endpoints of 𝑒 𝛺,𝐻(𝛩; 𝑖, 𝛬:)/ conclusions on the effects of a given intervention i over 
a given cohort 𝛬:, given the endpoints 𝛩 
 
Table 1. Summary of the components of credibility in an in silico clinical trial. 
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Since 1025 (when Ibn Sina completed the Canon of 
Medicine), the whole basis of the performance assessment of 
medical interventions has been that the mechanisms that 
regulate the disease and the effect of an intervention on it are 
too complex to be explored mechanistically and can be 
investigated only through observation. The intervention is 
trailed on a number of closely monitored patients, and if we do 
not observe any severe adverse effect, and the intervention 
shows to be effective in these patients, we authorise the use of 
such intervention on everyone.  
In other industrial sectors safety is largely ensured through 
modelling and simulation. It is inconceivable that a new large 
passenger airplane is produced in a few copies, which are run 
on test routes with real passengers, while we monitor if 
anything goes wrong; no passenger can board a new airplane 
design before its safety has been thoroughly tested through a 
combination in vitro and in silico methods.  
This is because for every known failure mode for an airplane 
a predictive model can be developed. As in silico methods 
develop and mature, both in breath of scope and credibility, 
there will be a growing opportunity for replacement, maybe 
computer simulations replacing physical experiments entirely. 
Probably the low-hanging fruits here are those situations where 
the animal model, or the standard clinical trial are already 
known to be poor predictors of the real-world safeness and/or 
effectiveness. As this revolution occurs, it will become vital to 
have a rigorous theoretical framing for the processes used to 
assess the credibility of in silico methods. We hope this paper 
can provide a first contribution in this direction. 
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